Literature DB >> 802670

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

S Moncada, R Gryglewski, S Bunting, J R Vane.   

Abstract

Microsomes prepared from rabbit or pig aortas transformed endoperoxides (PGG2 or PGH2) to an unstable substance (PGX) that inhibited human platelet aggregation. PGX was 30 times more potent in this respect than prostaglandin E1. PGX contracted some gastrointestinal smooth muscle and relaxed certain isolated blood vessels. Prostaglandin endoperoxides cause platelet aggregation possibly through the generation by platelets of thromboxane A2. Generation of PGX by vessel walls could be the biochemical mechanism underlying their unique ability to resist platelet adhesion. A balance between formation of anti- and pro-aggregatory substances by enzymes could also contribute to the maintenance of the integrity of vascular endothelium and explain the mechanism of formation of intra-arterial thrombi in certain physiopathological conditions.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 802670     DOI: 10.1038/263663a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  489 in total

1.  The Vineberg legacy: internal mammary artery implantation from inception to obsolescence.

Authors:  J L Thomas
Journal:  Tex Heart Inst J       Date:  1999

Review 2.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

Review 4.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

5.  Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells.

Authors:  Qi Liu; Yutao Xi; Toya Terry; Shui-Ping So; Anita Mohite; Jia Zhang; Geru Wu; Xiaobing Liu; Jie Cheng; Ke-He Ruan; James T Willerson; Richard A F Dixon
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

6.  The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.

Authors:  G Allan; M J Follenfant; P Lidbury; P L Oliver; B J Whittle
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

7.  Twenty-four- and 48-hour canine liver preservation by simple hypothermia with prostacyclin.

Authors:  M Monden; J G Fortner
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

8.  The effect of prostacyclin on cerebral vasospasm. An experimental study.

Authors:  L Quintana; R Konda; Y Ishibashi; T Yoshimoto; J Suzuki
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

9.  Effects of pyrimidines on the guinea-pig coronary vasculature.

Authors:  A J Vials; G Burnstock
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

10.  The importance of endogenous prostaglandins other than prostacyclin, for the modulation of contractility of some rabbit blood vessels.

Authors:  U Förstermann; G Hertting; B Neufang
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.